TACSTD2 and head and neck squamous cell carcinoma: Sacituzumab govitecan (SG), the most advanced Trop-2–directed ADC, is engineered to deliver cytotoxic therapy specifically to Trop-2–expressing tumors, which include HNSCC [135,136].